Literature DB >> 23812625

Scavenger receptor-BI is a receptor for lipoprotein(a).

Xiao-Ping Yang1, Marcelo J Amar, Boris Vaisman, Alexander V Bocharov, Tatyana G Vishnyakova, Lita A Freeman, Roger J Kurlander, Amy P Patterson, Lewis C Becker, Alan T Remaley.   

Abstract

Scavenger receptor class B type I (SR-BI) is a multi-ligand receptor that binds a variety of lipoproteins, including high density lipoprotein (HDL) and low density lipoprotein (LDL), but lipoprotein(a) [Lp(a)] has not been investigated as a possible ligand. Stable cell lines (HEK293 and HeLa) expressing human SR-BI were incubated with protein- or lipid-labeled Lp(a) to investigate SR-BI-dependent Lp(a) cell association. SR-BI expression enhanced the association of both (125)I- and Alexa Fluor-labeled protein from Lp(a). By confocal microscopy, SR-BI was also found to promote the internalization of fluorescent lipids (BODIPY-cholesteryl ester (CE)- and DiI-labeled) from Lp(a), and by immunocytochemistry the cellular internalization of apolipoprotein(a) and apolipoprotein B. When dual-labeled ((3)H-cholesteryl ether,(125)I-protein) Lp(a) was added to cells expressing SR-BI, there was a greater relative increase in lipid uptake over protein, indicating that SR-BI mediates selective lipid uptake from Lp(a). Compared with C57BL/6 control mice, transgenic mice overexpressing human SR-BI in liver were found to have increased plasma clearance of (3)H-CE-Lp(a), whereas mouse scavenger receptor class B type I knockout (Sr-b1-KO) mice had decreased plasma clearance (fractional catabolic rate: 0.63 ± 0.08/day, 1.64 ± 0.62/day, and 4.64 ± 0.40/day for Sr-b1-KO, C57BL/6, and human scavenger receptor class B type I transgenic mice, respectively). We conclude that Lp(a) is a novel ligand for SR-BI and that SR-BI mediates selective uptake of Lp(a)-associated lipids.

Entities:  

Keywords:  apolipoprotein(a); atherosclerosis; lipoprotein receptors; oxidized lipids; selective uptake

Mesh:

Substances:

Year:  2013        PMID: 23812625      PMCID: PMC3735942          DOI: 10.1194/jlr.M038877

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  33 in total

1.  Separation of plasma lipoproteins by density-gradient ultracentrifugation.

Authors:  T G Redgrave; D C Roberts; C E West
Journal:  Anal Biochem       Date:  1975-05-12       Impact factor: 3.365

2.  Extreme lipoprotein(a) levels and improved cardiovascular risk prediction.

Authors:  Pia R Kamstrup; Anne Tybjærg-Hansen; Børge G Nordestgaard
Journal:  J Am Coll Cardiol       Date:  2013-01-30       Impact factor: 24.094

3.  Receptor-mediated endocytosis of low-density lipoprotein in cultured cells.

Authors:  J L Goldstein; S K Basu; M S Brown
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

4.  Transport of lipids from high and low density lipoproteins via scavenger receptor-BI.

Authors:  H Stangl; M Hyatt; H H Hobbs
Journal:  J Biol Chem       Date:  1999-11-12       Impact factor: 5.157

Review 5.  The mysteries of lipoprotein(a).

Authors:  G Utermann
Journal:  Science       Date:  1989-11-17       Impact factor: 47.728

6.  Plasma Ip(a) concentration is inversely correlated with the ratio of Kringle IV/Kringle V encoding domains in the apo(a) gene.

Authors:  D Gavish; N Azrolan; J L Breslow
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

Review 7.  The role of scavenger receptor class B type I (SR-BI) in lipid trafficking. defining the rules for lipid traders.

Authors:  David Rhainds; Louise Brissette
Journal:  Int J Biochem Cell Biol       Date:  2004-01       Impact factor: 5.085

8.  Metabolism of HDL-cholesteryl ester in the rat, studied with a nonhydrolyzable analog, cholesteryl linoleyl ether.

Authors:  Y Stein; Y Dabach; G Hollander; G Halperin; O Stein
Journal:  Biochim Biophys Acta       Date:  1983-06-16

9.  Overexpression of hepatic lipase in transgenic rabbits leads to a marked reduction of plasma high density lipoproteins and intermediate density lipoproteins.

Authors:  J Fan; J Wang; A Bensadoun; S J Lauer; Q Dang; R W Mahley; J M Taylor
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-30       Impact factor: 11.205

10.  Acetoacetylated lipoproteins used to distinguish fibroblasts from macrophages in vitro by fluorescence microscopy.

Authors:  R E Pitas; T L Innerarity; J N Weinstein; R W Mahley
Journal:  Arteriosclerosis       Date:  1981 May-Jun
View more
  33 in total

1.  Experimental challenges regarding the in vitro investigation of the nanoparticle-biocorona in disease states.

Authors:  Sherleen Xue-Fu Adamson; Zhoumeng Lin; Ran Chen; Lisa Kobos; Jonathan Shannahan
Journal:  Toxicol In Vitro       Date:  2018-05-05       Impact factor: 3.500

2.  PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role.

Authors:  Frederick J Raal; Robert P Giugliano; Marc S Sabatine; Michael J Koren; Dirk Blom; Nabil G Seidah; Narimon Honarpour; Armando Lira; Allen Xue; Padmaja Chiruvolu; Simon Jackson; Mei Di; Matthew Peach; Ransi Somaratne; Scott M Wasserman; Rob Scott; Evan A Stein
Journal:  J Lipid Res       Date:  2016-04-21       Impact factor: 5.922

3.  HDL-C, ABCA1-mediated cholesterol efflux, and lipoprotein(a): insights into a potential novel physiologic role of lipoprotein(a).

Authors:  Calvin Yeang; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2015-05-26       Impact factor: 5.922

4.  Lipoprotein(a) Mass Levels Increase Significantly According to APOE Genotype: An Analysis of 431 239 Patients.

Authors:  Patrick M Moriarty; Stephen A Varvel; Philip L S M Gordts; Joseph P McConnell; Sotirios Tsimikas
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-01-05       Impact factor: 8.311

Review 5.  Tolerogenic dendritic cells in organ transplantation.

Authors:  Jordi Ochando; Farideh Ordikhani; Stefan Jordan; Peter Boros; Angus W Thomson
Journal:  Transpl Int       Date:  2019-10-29       Impact factor: 3.782

6.  Critical residues and motifs for homodimerization of the first transmembrane domain of the plasma membrane glycoprotein CD36.

Authors:  Peng Wei; Fu-de Sun; Li-Min Zuo; Jing Qu; Peng Chen; Li-da Xu; Shi-Zhong Luo
Journal:  J Biol Chem       Date:  2017-03-23       Impact factor: 5.157

Review 7.  NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis.

Authors:  Sotirios Tsimikas; Sergio Fazio; Keith C Ferdinand; Henry N Ginsberg; Marlys L Koschinsky; Santica M Marcovina; Patrick M Moriarty; Daniel J Rader; Alan T Remaley; Gissette Reyes-Soffer; Raul D Santos; George Thanassoulis; Joseph L Witztum; Simhan Danthi; Michelle Olive; Lijuan Liu
Journal:  J Am Coll Cardiol       Date:  2018-01-16       Impact factor: 24.094

Review 8.  Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease.

Authors:  Michael B Boffa
Journal:  Curr Atheroscler Rep       Date:  2016-12       Impact factor: 5.113

Review 9.  SR-BI: A Multifunctional Receptor in Cholesterol Homeostasis and Atherosclerosis.

Authors:  MacRae F Linton; Huan Tao; Edward F Linton; Patricia G Yancey
Journal:  Trends Endocrinol Metab       Date:  2017-03-01       Impact factor: 12.015

10.  A Not-So-Little Role for Lipoprotein(a) in the Development of Calcific Aortic Valve Disease.

Authors:  Maximillian A Rogers; Elena Aikawa
Journal:  Circulation       Date:  2015-07-29       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.